跳至主要内容
临床试验/NCT03125499
NCT03125499已完成不适用

A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees

OrthoTrophix, Inc1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2017年7月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
54
试验地点
1
主要终点
Evaluate the long-term changes in patellar cartilage thickness

研究概览

简要总结

To evaluate the long-term changes in patellar cartilage thickness in TPX-100 versus placebo-treated knees in subjects who participated in Study TPX-100-1 or TPX-100-2.

详细描述

No drug intervention. Study to collect 1 additional MRI of each knee treated in either TPX-100-1 or TPX-100-2.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
25 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who participated in TPX-100-1 and received 4 injections of 200 mg/injection TPX-100 in one knee, or subjects who participated in TPX-100
  • Cruciate and collateral ligament stability as assessed by screening history and clinical examination
  • Stable medial and lateral menisci as assessed by screening history and clinical examination
  • Able to read, understand, sign and date the subject informed consent

排除标准

  • Contraindication to MRI, including: metallic fragments, clips or devices in the brain, eye, or spinal canal; implanted devices that are magnetically programmed; weight > 300 lbs.; moderate or severe claustrophobia; previous intolerance of MRI procedure
  • Prior surgery in the knees, excluding procedures for debridement only (no previous microfracture procedure)
  • History of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or infectious cause for arthritis
  • Last viscosupplementation (e.g. Synvisc® or similar hyaluronic acid product) injected into either knee < 3 months before enrollment
  • Last intra-articular knee injection of corticosteroids < 3 months before enrollment
  • Use of any steroids (except inhaled corticosteroids for allergy or respiratory problems) during the previous month before enrollment
  • History of arthroscopy in either knee in the 3 months before enrollment
  • History of septic arthritis, gout or pseudo-gout in either knee in the 12 months before enrollment
  • Clinical signs of acute meniscal tear (locking, new acute mechanical symptoms consistent with meniscal tear)
  • Active systemic infection
  • Participation in other clinical osteoarthritis drug studies, except for studies TPX-100-1 and TPX-100-2, within two years prior to enrollment in TPX-100-4.

结局指标

主要结局

Evaluate the long-term changes in patellar cartilage thickness

时间窗: Between 24 and 34 months from initial drug treatment

Quantitative analysis of long-term changes in patellar cartilage thickness by MRI

次要结局

  • Examine intra-subject longitudinal changes in patellar cartilage volume between TPX-100 versus placebo-treated knees by MRI(Between 24 and 34 months from initial drug treatment)
  • Examine intra-subject longitudinal changes in thickness and thinness scores of cartilage in the central (non-patellar) compartment of knees(Between 24 and 34 months from initial drug treatment)
  • Examine intra-subject longitudinal changes in Patient reported outcome measures(Between 24 and 34 months from initial drug treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Prospective Observational Study to Evaluate... | 临床试验